Clinical trials: Swallowing Disorders
Gastroesophageal Reflux Disease
Diagnosis and Response to Treatment Using a Reliable Gastroesophageal Reflux Disease (GERD) Questionnaire: An In Clinical Practice Study
The purpose of the study is to determine the applicability and utility of Gerd Q in the diagnosis of GERD and in the assessment of treatment response.
- Trial name
- GQS (NCT00963144)
- Where
- 2 sites in Malaysia
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Chest Pain, Gastroesophageal Reflux
Chest Pain Pilot Study
The purpose of this study is to compare the efficacy of Nexium® with placebo in relief of acid related pain or discomfort in the chest.
- Trial name
- NCT00251901
- Testing
- Esomeprazole
- Where
- 80 sites in Canada, Denmark and 4 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux, Heartburn
A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)
The purpose of this study is to assess the efficacy and safety of long-term, "on-demand" maintenance therapy with rabeprazole in patients with non-erosive reflux disease (NERD).
- Trial name
- NCT00236392
- Testing
- rabeprazole
- Volunteers
- 422 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Gastroesophageal Reflux Disease (GERD)
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD)…
- Trial name
- NCT03561883
- Testing
- IW-3718, Standard-dose PPIs QD
- Where
- 101 sites in United States, Canada
- Volunteers
- 609 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
GERD
Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
This study is a randomised, double-blind, parallel-group and placebo controlled study comparing the efficacy of esomeprazole 40 mg orally qd vs. placebo and esomeprazole 20 mg orally qd vs.
- Trial name
- NCT00241540
- Testing
- Esomeprazole
- Where
- 119 sites in United States, Belgium and 4 more
- Volunteers
- 808 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
A Cross-sectional Study on the Prevalence and Extraesophageal Symptoms of Gastroesophageal Reflux Disease(GERD) in Patients With Upper GI Symptoms, Visiting the Outpatient Departments of Peripheral Hospitals in Greece
The present study has been designed to provide current data on GERD prevalence in several regional areas of Greece outside the two major urban centres (Athens and Thessaloniki), to measure the treatment response in GERD patients…
- Trial name
- GERDQ-XS (NCT01215305)
- Where
- 19 sites in Greece
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Symptomatic Non-erosive Gastroesophageal Reflux Disease
A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks
The main objective is to assess the efficacy of vonoprazan (10 mg as needed) compared to placebo (as needed) in relief of episodic heartburn at 2 hours that is sustained for 24 hours over 12 weeks of treatment in participants…
- Trial name
- NCT07752407
- Testing
- Vonoprazan
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
The Aim of This Study is to Investigate the Frequency and Related Risk Factors of Recurrence, and Quality of Life in Patients With GERD After Treatment With PPI
Recurrence Rate, Risk Factors for the Recurrence, and Quality of Life in Patients With GERD in Korea-an Observational
Recurrence rate, risk factors for the recurrence, and quality of life in patients with GERD in Korea-an observational study.
- Trial name
- Refresh (NCT01378338)
- Where
- 10 sites in South Korea
- Volunteers
- 855 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
The Clinical Significance of Minimal Change in Reflux Esophagitis Based on the Gastroesophageal Reflux Disease Questionnaire
The purpose of this study is to define the endoscopic findings of minimal change that is significant to clinical significant reflux esophagitis.
- Trial name
- MIGHT (NCT00901004)
- Where
- 7 sites in South Korea
- Volunteers
- 1,550 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Prevalence and Impact in Work Productivity of Gastroesophageal Reflux Disease (GERD) in Primary Care Patients With Upper Gastrointestinal (GI) Symptoms Using GerdQ
The purpose of the study is to provide data on the GERD prevalence as percentage of patients with upper GI symptoms that are identified with GERD using the GerdQ Questionnaire.
- Trial name
- GerdQ-Greece (NCT00914342)
- Where
- 54 sites in Greece
- Volunteers
- 889 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux in Children
Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR)
The aim of the study is to assess the effectiveness of this new formula on regurgitations and secondarily its effect on digestive tolerance through a randomized, controlled, double-blind trial against a comparator.
- Trial name
- STELLAR (NCT04358146)
- Testing
- Experimental Infant formula, Infant formula thickened with locust bean gum
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 346 people
- Sponsor
- United Pharmaceuticals
Gastroesophageal Reflux Disease
A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab
This observation study is a large-scale, prospective, and multi-organ observation study to observe the improvement effect of the self-evaluation results (PRO) of erosive gastroesophageal reflux disease at least 4 to 8 weeks after…
- Trial name
- NCT05660122
- Testing
- Fexuprazan Hydrochloride
- Where
- South Korea
- Volunteers
- 2,852 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Gastroesophageal Reflux Disease
Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease
The EndoStim Stimulation System is an investigational device intended to improve the lower esophageal sphincter (LES) resting tone and restore LES function in individuals suffering with gastroesophageal reflux disease (GERD).
- Trial name
- NCT01578642
- Testing
- EndoStim LES Stimulation System
- Where
- Chile
- Volunteers
- 24 people
- Sponsor
- EndoStim Inc.
GERD
A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects
To compare pharmacokinetics, pharmacodynamics and safety after single/multiple administration of CKD-382 and D026 in healthy subjects
- Trial name
- NCT04703374
- Testing
- CKD-382(formulation I), CKD-382(formulation II), D026
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Gastroesophageal Reflux Disease
Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients
This study is designed to evaluate the efficacy and tolerability of ilaprazole relative to that of esomeprazole in healing erosive esophagitis and resolving accompanying symptoms of GERD.
- Trial name
- NCT02860624
- Testing
- 10 mg ilaprazole, 40mg esomeprazole
- Volunteers
- 550 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Gastroesophageal Reflux
Safety and Efficacy of Lansoprazole in Patients With Reflux Disease
The purpose of this study is to measure the safety, efficacy and quality of life of lansoprazole in patients with reflux disease over a five year period.
- Trial name
- NCT01135368
- Testing
- Lansoprazole
- Volunteers
- 506 people
- Sponsor
- Takeda
Regurgitation, Gastric
Evaluation of the Tolerance and Safety of a New Partly Fermented Anti-regurgitation Infant Formula
A randomised, controlled, double-blind trial to evaluate the tolerance and safety of a new partly fermented anti-regurgitation infant formula containing prebiotics and locust bean gum in infants with regurgitation.
- Trial name
- Leopard (NCT03371615)
- Testing
- Anti-regurgitation infant formula
- Where
- 2 sites in Poland
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Nutricia Research
Gastroesophageal Reflux Disease
The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux
The purpose of this study is to assess the safety and efficacy of lansoprazole microgranules oral suspension, once daily (QD), in infants with gastroesophageal reflux symptoms during a 4-week treatment period.
- Trial name
- NCT00324974
- Testing
- Lansoprazole microgranules suspension
- Where
- 17 sites in United States, Poland
- Volunteers
- 162 people
- Sponsor
- Takeda
Gastroesophageal Reflux, Heartburn
A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)
The purpose of the study is to confirm the safety and effectiveness of rabeprazole in the treatment of patients with erosive or ulcerative gastroesophageal reflux disease (GERD) in routine primary health care.
- Trial name
- NCT00216489
- Testing
- rabeprazole sodium
- Volunteers
- 191 people
- Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
Aortic Regurgitation
HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation
To evaluate the safety and performance of The Meridian® TAVR Valve in patients with severe aortic regurgitation who present at high risk for aortic valve replacement surgery.
- Trial name
- RIVAL - AR EFS (NCT05409378)
- Testing
- The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)
- Where
- 3 sites in United States
- Sponsor
- HLT Inc.